Omaveloxolone is primarily investigated for its potential therapeutic applications in treating mitochondrial diseases and inflammatory conditions. It functions as an activator of Nrf2, a transcription factor that regulates antioxidant response, helping to reduce oxidative stress and inflammation in cells. This makes it a promising candidate for conditions like Friedreich's ataxia, a genetic disorder that leads to progressive nervous system damage and movement issues. Additionally, its anti-inflammatory properties are being explored for other neurodegenerative diseases and conditions where oxidative stress plays a key role in disease progression. Clinical trials are ongoing to evaluate its efficacy and safety in these areas.